Literature DB >> 23045466

Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series.

Julia Brinkmann1, Karsten Heusser, Bernhard M Schmidt, Jan Menne, Gunnar Klein, Johann Bauersachs, Hermann Haller, Fred C Sweep, Andre Diedrich, Jens Jordan, Jens Tank.   

Abstract

Endovascular renal nerve ablation has been developed to treat resistant hypertension. In addition to lowering efferent renal sympathetic activation, the intervention may attenuate central sympathetic outflow through decreased renal afferent nerve traffic, as evidenced by a recent case report. We tested the hypothesis in 12 nonpreselected patients with difficult-to-control hypertension (aged 45-74 years) admitted for renal nerve ablation. All patients received ≥ 3 antihypertensive medications at full doses, including a diuretic. Electrocardiogram, respiration, brachial and finger arterial blood pressure, and muscle sympathetic nerve activity were recorded before and 3 to 6 months after renal nerve ablation. Heart rate and blood pressure variability were analyzed in the time and frequency domain. Pharmacological baroreflex slopes were determined using the modified Oxford bolus technique. Resting heart rate was 61 ± 3 bpm before and 58 ± 2 bpm after ablation (P = 0.4). Supine blood pressure was 157 ± 7/85 ± 4 mm Hg before and 157 ± 6/85 ± 4 mm Hg after ablation (P = 1.0). Renal nerve ablation did not change resting muscle sympathetic nerve activity (before, 34 ± 2 bursts per minute; after, 32 ± 3 bursts per minute P = 0.6), heart rate variability, or blood pressure variability. Pharmacological baroreflex control of heart rate and muscle sympathetic nerve activity did not change. We conclude that reduced central sympathetic inhibition may be the exception rather than the rule after renal nerve ablation in unselected patients with difficult-to-control arterial hypertension.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23045466     DOI: 10.1161/HYPERTENSIONAHA.112.201186

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  58 in total

1.  [Interventional strategies in hypertension management].

Authors:  R Wachter; J Menne
Journal:  Internist (Berl)       Date:  2015-03       Impact factor: 0.743

2.  Can physiology zap therapeutic sweet spots in hypertension?

Authors:  Michael J Joyner
Journal:  Hypertension       Date:  2012-10-08       Impact factor: 10.190

Review 3.  Sympathetic hyperactivity in chronic kidney disease: pathophysiology and (new) treatment options.

Authors:  Eva E Vink; Rosa L de Jager; Peter J Blankestijn
Journal:  Curr Hypertens Rep       Date:  2013-04       Impact factor: 5.369

Review 4.  Device-Based Therapy for Drug-Resistant Hypertension: An Update.

Authors:  Ping Li; Mark Nader; Kousalya Arunagiri; Vasilios Papademetriou
Journal:  Curr Hypertens Rep       Date:  2016-08       Impact factor: 5.369

Review 5.  Modulation of Sympathetic Overactivity to Treat Resistant Hypertension.

Authors:  Raven Voora; Alan L Hinderliter
Journal:  Curr Hypertens Rep       Date:  2018-09-07       Impact factor: 5.369

6.  Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?

Authors:  J Rosa; T Zelinka; O Petrák; B Štrauch; Z Šomlóová; T Indra; R Holaj; K Čurila; P Toušek; M Šenitko; P Widimský; J Widimský
Journal:  J Hum Hypertens       Date:  2014-02-06       Impact factor: 3.012

7.  Ethnicity and sympathetic tone: predictors of the blood pressure response to renal denervation?

Authors:  Yutang Wang
Journal:  Nat Rev Cardiol       Date:  2014-09-30       Impact factor: 32.419

Review 8.  The sympathetic nervous system alterations in human hypertension.

Authors:  Guido Grassi; Allyn Mark; Murray Esler
Journal:  Circ Res       Date:  2015-03-13       Impact factor: 17.367

Review 9.  Renal sympathetic denervation in therapy resistant hypertension - pathophysiological aspects and predictors for treatment success.

Authors:  Karl Fengler; Karl Philipp Rommel; Thomas Okon; Gerhard Schuler; Philipp Lurz
Journal:  World J Cardiol       Date:  2016-08-26

Review 10.  Dysfunctional brain-bone marrow communication: a paradigm shift in the pathophysiology of hypertension.

Authors:  Monica M Santisteban; Jasenka Zubcevic; David M Baekey; Mohan K Raizada
Journal:  Curr Hypertens Rep       Date:  2013-08       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.